Paricalcitol Improves Anemia of Inflammation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
Anemia of inflammation (AI) is a common comorbidity in hemodialysis patients. Paricalcitol is a selective vitamin D receptor activator with potential benefits on anti-inflammatory cytokines expression. The paricalcitol for the secondary hyperparathyroidism control may improve AI decreasing erythropoietin stimulating agents (ESAs) dosage.
Epistemonikos ID: 3324ddc95200be14fcaa56c6aeec6ab11c9a4314
First added on: Jun 14, 2024